This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Roche Holding AG

Drug Names(s): PRO97796

Description: BR3-Fc is a molecule designed to bind to BAFF, a secreted survival factor that is involved in the cascade leading to the survival of B-cells. Interrupting this cascade results in the death of B-cells and therefore may have potential as a therapeutic in B-cell mediated diseases.

Deal Structure: BR3-Fc was jointly developed by Genentech and Biogen Idec.

In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.

Partners: Biogen, Inc.

BR3-Fc News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug